Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL

SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL

December 20, 2024

SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL

Next: VOLUNTARY ANNOUNCEMENT FIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020) OBTAINS FURTHER CLINICAL TRIAL APPROVAL FOR NEW INDICATION

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat